Zivadinov Robert, Munschauer Frederick E, Ramanathan Murali, Benedict Ralph H B, Weinstock-Guttman Bianca
Buffalo Neuroimaging Analysis Center, Department of Neurology, University at Buffalo, State University of New York, Buffalo, New York 14203, USA.
Drugs Today (Barc). 2008 Aug;44(8):601-13. doi: 10.1358/dot.2008.44.8.1242250.
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system (CNS). Interferon (IFN) beta products are potent antiinflammatory and immunomodulatory agents that interfere with the autoimmune processes in MS and reduce CNS damage. Once-weekly intramuscular IFN beta-1a slows the progression of neurologic and cognitive disability, reduces the frequency of relapses and inflammatory lesion burden, and preserves cognitive function. It has a positive effect on both conventional and nonconventional measures of magnetic resonance imaging (MRI) and reduces the progression of brain atrophy, predominantly due to reduced grey matter atrophy. Early initiation of disease-modifying therapy after the diagnosis of relapsing-remitting MS or after a single demyelinating event (and evidence of lesions on MRI) allows patients the opportunity to obtain maximal long-term benefits.
多发性硬化症（MS）是一种中枢神经系统（CNS）的慢性炎性脱髓鞘疾病。β-干扰素产品是强效抗炎和免疫调节药物，可干扰MS中的自身免疫过程并减少中枢神经系统损伤。每周一次的肌肉注射β-1a干扰素可减缓神经和认知功能障碍的进展，降低复发频率和炎性病变负担，并保留认知功能。它对磁共振成像（MRI）的传统和非传统测量指标均有积极影响，并减少脑萎缩的进展，主要是由于灰质萎缩减少。在复发缓解型MS诊断后或单次脱髓鞘事件后（以及MRI上有病变证据）尽早开始疾病修饰治疗，可使患者有机会获得最大的长期益处。
